Process for preparation of macrocyclic chelant and metal complexes
Summary
USPTO granted patent US12590073B2 to Biophore India Pharmaceuticals Pvt. Ltd. for an improved process preparing macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid and its gadolinium/calcium metal complexes with purity exceeding 99.0% by HPLC. The patent names inventors Manik Reddy Pullagurla and Jagadeesh Babu Rangisetty, with 9 claims granted.
What changed
USPTO granted patent US12590073B2 to Biophore India Pharmaceuticals Pvt. Ltd. covering an improved synthesis process for macrocyclic chelant 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl triacetic acid (formula 1) and its paramagnetic metal complexes. The patent specifies processes for preparing gadolinium complex (formula 1a) and novel calcium complex (formula 1b) with HPLC purity greater than 99.0%. The patent issued March 31, 2026, with application number 17288146 and 9 claims.
Companies developing gadolinium-based contrast agents or macrocyclic chelate technologies should review this patent to assess potential freedom-to-operate implications. Competitors seeking to manufacture similar compounds will need to design around these claims or pursue licensing arrangements with Biophore India. No immediate compliance actions or deadlines apply as this is a granted patent rather than a regulatory requirement.
What to do next
- Review patent claims to assess freedom-to-operate for competing macrocyclic chelant technologies
- Consider design-around strategies if developing similar processes
- Evaluate potential licensing opportunities with Biophore India if the technology is relevant to product development
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Process for the preparation of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetra azacyclododecane-1,4,7-triyl) triacetic acid and it's complexes with paramagnetic metal ions
Grant US12590073B2 Kind: B2 Mar 31, 2026
Assignee
BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.
Inventors
Manik Reddy Pullagurla, Jagadeesh Babu Rangisetty
Abstract
The present invention relates to an improved process for the preparation of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to the process for the preparation of metal complexes of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1) with purity greater than 99.0% by HPLC. The present invention also relates to an improved process for the preparation of gadolinium complex of formula (1a) with macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to a novel process for the preparation of calcium complex of formula (1b) with macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1).
CPC Classifications
C07D 257/02
Filing Date
2019-10-23
Application No.
17288146
Claims
9
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.